Answers are grounded in this paper and cite their sources.
Catherine D. Chong has received research funding from the American Heart Association, Amgen, National Institutes of Health, and United States Department of Defense. Sait Ashina has been a consultant for Abbvie/Allergan, Amgen, Biohaven, Eli Lilly, Novartis, Pfizer, Supernus, Teva, Theranica, Percept, and Impel Neuropharma. Joshua Kamins serves on the speaker bureau for Lundbeck. Ann Scher has received research support from Eli Lilly. The views expressed are those of the authors and do not necessarily reflect the official policy of the Uniformed Services University or the US Department of Defense. Carlyn Patterson Gentile has received salary support in the past 24 months from grants from the American Academy of Neurology, the International Headache Academy sponsored by the American Headache Society, and the Children's Hospital of Philadelphia/University of Pennsylvania NeuroNEXT fellowship. Alan Finkel declares no conflicts of interest. Michael L. Oshinsky is a federal employee of NIH and has no conflict of interest to report. Within the prior 24 months Todd J. Schwedt has received compensation for consulting with AbbVie, Allergan, Amgen, Axsome, Biodelivery Science, Biohaven, Collegium, Eli Lilly, Linpharma, Lundbeck, Satsuma, Scilex, and Theranica and royalties from UpToDate. He has stock options in Aural Analytics and Nocira. He has received research funding from the American Heart Association, Amgen, Henry Jackson Foundation, National Institutes of Health, Patient Centered Outcomes Research Institute, Spark Neuro, and United States Department of Defense.
No takes yet. Share an insight, caveat, or question.
Chong et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: